Ganwei
PreclinicalBiologic
Ganwei is one of 64 biologic programs targeting Non-Alcoholic Fatty Liver Disease. It is currently in Preclinical.
2
Indications
2
Total Trials
1
Active Trials
63
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
101 competitors in Non-Alcoholic Fatty Liver Disease
#DrugCompanyPhaseTrials
1Deltavit
HHyundai Pharmaceutical Co., LTD.
Phase 3
Aquasol E
NNational Eye Institute (NEI)
Phase 3
Rezdiffra
Madrigal PharmaceuticalsPhase 3
Lipaglyn
ZZydus Therapeutics Inc.
Phase 3
Omacor
AstraZenecaPhase 3
Byetta
AstraZenecaPhase 2
Precose
BayerPhase 2
Investigational Treatment
NovartisPhase 3
Glucophage
EMD SeronoPhase 2
Ocaliva
IIntercept Pharmaceuticals
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ganwei. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Preclinical[1]
- Company
- TTaipei City Hospital